Literature DB >> 8786287

CD40-mediated signaling in B cells. Balancing cell survival, growth, and death.

M R Kehry1.   

Abstract

Multimerization of CD40 molecules on B cells by binding CD40 ligand on activated T cells initiates signaling events essential for B cell differentiation. In mature B cells, CD40 mediates stimulation and costimulation of cell growth, switch recombination, and transcriptional regulation. CD40-mediated signaling also regulates cell death, rescuing B cells from anti-Ig-induced apoptosis and inducing the expression of the Fas surface molecule. Recent efforts to elucidate the biochemistry of CD40-mediated signaling pathways have identified members of the TRAF protein family that are associated with the cytoplasmic tail of CD40. CD40 cross-linking probably multimerizes TRAF proteins which may act as direct transcriptional regulators. Modulation of protein tyrosine kinase and protein tyrosine phosphatase activity also occurs after CD40-mediated signaling; however, a connection to the TRAF pathway has not been established. Multiple pathways of B cell triggering are probably integrated at the level of transcriptional activation to produce differentiation stage-specific B cell responses.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8786287

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  39 in total

1.  The Epstein-Barr virus oncoprotein latent membrane protein 1 engages the tumor necrosis factor receptor-associated proteins TRADD and receptor-interacting protein (RIP) but does not induce apoptosis or require RIP for NF-kappaB activation.

Authors:  K M Izumi; E D Cahir McFarland; A T Ting; E A Riley; B Seed; E D Kieff
Journal:  Mol Cell Biol       Date:  1999-08       Impact factor: 4.272

2.  NF-kappaB-mediated up-regulation of Bcl-x and Bfl-1/A1 is required for CD40 survival signaling in B lymphocytes.

Authors:  H H Lee; H Dadgostar; Q Cheng; J Shu; G Cheng
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-03       Impact factor: 11.205

3.  Atherosclerosis: the emerging role of inflammation and the CD40-CD40 ligand system.

Authors:  R P Phipps
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-20       Impact factor: 11.205

4.  CD40 signaling in human dendritic cells is initiated within membrane rafts.

Authors:  P O Vidalain; O Azocar; C Servet-Delprat; C Rabourdin-Combe; D Gerlier; S Manié
Journal:  EMBO J       Date:  2000-07-03       Impact factor: 11.598

Review 5.  Life and death within germinal centres: a double-edged sword.

Authors:  Liliana Guzman-Rojas; Jennifer C Sims-Mourtada; Roberto Rangel; Hector Martinez-Valdez
Journal:  Immunology       Date:  2002-10       Impact factor: 7.397

6.  Toll-like receptors 2 and 4 are differentially involved in Fas dependent apoptosis in Peyer's patch and the liver at an early stage after bile duct ligation in mice.

Authors:  A Ogawa; T Tagawa; H Nishimura; T Yajima; T Abe; T Arai; M Taniguchi; K Takeda; S Akira; Y Nimura; Y Yoshikai
Journal:  Gut       Date:  2005-08-23       Impact factor: 23.059

7.  CD30 is a CD40-inducible molecule that negatively regulates CD40-mediated immunoglobulin class switching in non-antigen-selected human B cells.

Authors:  A Cerutti; A Schaffer; S Shah; H Zan; H C Liou; R G Goodwin; P Casali
Journal:  Immunity       Date:  1998-08       Impact factor: 31.745

8.  The Epstein-Barr virus LMP1 amino acid sequence that engages tumor necrosis factor receptor associated factors is critical for primary B lymphocyte growth transformation.

Authors:  K M Izumi; K M Kaye; E D Kieff
Journal:  Proc Natl Acad Sci U S A       Date:  1997-02-18       Impact factor: 11.205

Review 9.  Design of CD40 agonists and their use in growing B cells for cancer immunotherapy.

Authors:  Richard S Kornbluth; Mariusz Stempniak; Geoffrey W Stone
Journal:  Int Rev Immunol       Date:  2012-08       Impact factor: 5.311

Review 10.  The platelet as an immune cell-CD40 ligand and transfusion immunomodulation.

Authors:  Neil Blumberg; Sherry L Spinelli; Charles W Francis; Mark B Taubman; Richard P Phipps
Journal:  Immunol Res       Date:  2009-01-29       Impact factor: 2.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.